查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1620754

月經症候群治療藥物市場：按藥物類型、類型和分銷管道分類 - 全球預測 2025-2030

Premenstrual Syndrome Treatment Market by Drug Type (Antidepressants, Diuretics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs)), Type (Over-the-Counter, Prescription), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年月經症候群治療藥物市場價值為17.2億美元，預計到2024年將達到17.9億美元，複合年成長率為4.35%，到2030年將達到23.2億美元。

月經症候群 (PMS) 治療市場圍繞著一系列旨在緩解經前症候群 (PMS) 症狀的治療方法和產品展開，經前症候群影響了很大一部分月經人群。經前症候群的廣泛流行證明了對這個市場的需求，經前症候群會導致身體、情緒和行為症狀，嚴重影響日常生活和生活品質。經前症候群藥物的用途包括非處方藥、補充品和改變生活方式，以及解決情緒低落、腹脹和痙攣等特定症狀的處方治療。最終使用者主要是尋求緩解這些症狀的個人，包括自我用藥的個人和在醫生監督下的個人。該市場的成長受到人們意識的提高、女性醫療保健的進步以及對個人化醫療日益成長的偏好的顯著影響。開發基於激素的治療方法、植物來源的治療方法以及用於症狀追蹤和管理的數位健康解決方案存在機會。然而，這個市場面臨一些限制，例如當前治療方法的副作用和阻礙公開討論和診斷的社會恥辱，以及核准新治療方法的監管挑戰。此外，由於經前症候群的多方面性質，沒有一刀切的治療方法，這是一個問題。可以探索非荷爾蒙治療方案、用於個人化治療的人工智慧以及增強患者參與度的行動醫療技術等創新。對導致經前症候群的特定遺傳、荷爾蒙和生活方式因素的研究可能會為更有針對性的干涉措施提供見解。經前症候群治療市場充滿活力，對提供全面症狀緩解的有效解決方案的需求持續成長。治療公司正在利用未滿足的需求並透過專注於以患者為中心的方法、進行宣傳宣傳活動以減少恥辱以及與醫療專業人員合作最佳化治療通訊協定來獲得市場動力，這可能會導致成長和患者結果的改善。

主要市場統計
基準年[2023] 17.2億美元
預測年份 [2024] 17.9億美元
預測年份 [2030] 23.2億美元
複合年成長率（%） 4.35%

市場動態：快速發展的月經症候群治療市場的關鍵市場洞察

供需的動態交互作用正在改變經月經症候群藥物的市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 提高月經症候群的診斷意識
    • 透過線上管道輕鬆獲得經前症候群治療產品
  • 市場限制因素
    • 與 PMS 治療藥物和設備產品召回相關的問題
  • 市場機會
    • 經前症候群治療進展及新藥出現
    • 穿戴式科技的採用和數位健康的普及
  • 市場挑戰
    • 有關 PMS 管理的社會障礙與污名化

波特五力：駕馭月經症候群藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對月經症候群治療市場的影響

外部宏觀環境因素在塑造月經症候群治療藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解月經症候群治療藥物市場的競爭狀況

月經症候群治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV月經症候群治療藥物市場定位矩陣供應商績效評估

FPNV 定位矩陣是評估經月經症候群治療藥物市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃經月經症候群治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對月經症候群治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高對月經症候群相關診斷的認知
      • 透過線上管道輕鬆獲得經前症候群治療產品
    • 抑制因素
      • 與 PMS 藥品和設備產品召回相關的問題
    • 機會
      • 經前症候群治療的進展與新藥的出現
      • 穿戴式科技的引入和數位健康的傳播
    • 任務
      • 有關經前症候群管理的社會障礙和恥辱
  • 市場區隔分析
    • 藥物類型：由於口服避孕藥具有避孕和症狀管理的雙重作用，因此擴大用於管理經前症候群症狀。
    • 分銷管道：由於顧客便捷的購物需求，電子商務分銷管道正成為首選。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類型分類的經月經症候群治療藥物市場

  • 抗憂鬱症
  • 利尿劑
  • 非類固醇消炎劑(NSAID)
  • 口服避孕藥和卵巢抑制劑

第7章月經症候群治療藥物市場：依類型

  • 在商店
  • 處方箋

第8章月經症候群治療藥物市場：按分銷管道

  • 電子商務
  • 醫院
  • 零售藥房

第9章北美和南美月經症候群治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太經月經症候群治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲月經症候群治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Vistagene 宣布 PH80 用於急性管理經月經焦慮症症狀的探索性 2A 期研究取得正面結果
    • 三十麥迪遜醫院將透過從 The Pill Club 策略收購資產，為數千名患者提供連續性護理，並加強其在女性健康領域的地位。
    • 總部位於倫敦的神經科技Start-Ups開發治療月經症狀的醫療設備
  • 戰略分析和建議

公司名單

  • AA Pharma Inc.
  • Alfa Pharma GmbH
  • Asarina Pharma AB.
  • ASKA Pharmaceutical Co., Ltd.
  • Aurobindo Pharma
  • Bayer AG
  • Cadila Pharmaceuticals.
  • Comforte Cream by PMS4PMS, LLC
  • Dr. Reddy's Laboratories Inc.
  • GlaxoSmithKline plc
  • Intas Pharmaceuticals Ltd.
  • Lupin Limited
  • Mylan NV
  • Par Pharmaceutical, Inc
  • Pfizer Inc.
  • Samphire Neuroscience
  • Shine Pharmaceuticals Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Himalaya Drug Company
  • Vitane Pharmaceuticals, Inc.
Product Code: MRR-4F1ADAF481D9

The Premenstrual Syndrome Treatment Market was valued at USD 1.72 billion in 2023, expected to reach USD 1.79 billion in 2024, and is projected to grow at a CAGR of 4.35%, to USD 2.32 billion by 2030.

Premenstrual Syndrome (PMS) Treatment Market is centered around the array of therapies and products designed to alleviate symptoms of PMS, which affects a significant proportion of menstruating individuals. The necessity of this market is underscored by the widespread prevalence of PMS, which can cause physical, emotional, and behavioral symptoms, substantially impacting daily activities and quality of life. Applications of PMS treatments span from over-the-counter medications, supplements, and lifestyle modifications to prescription therapies, tailored to address specific symptoms like mood swings, bloating, and cramps. End-users primarily encompass individuals seeking relief from these symptoms, including both those self-treating and those under medical supervision. Growth in this market is significantly influenced by increasing awareness, advances in women's healthcare, and a rising preference for personalized medicine. Opportunities exist in developing hormone-based treatments, plant-based remedies, and digital health solutions for symptom tracking and management. However, the market faces limitations such as side effects of current treatments, and societal stigma that hinders open discussions and diagnosis, coupled with regulatory challenges in approving new therapies. Additionally, the absence of a one-size-fits-all treatment due to the multifaceted nature of PMS presents challenges. Innovations could be explored in non-hormonal treatment options, artificial intelligence for personalized treatments, and mobile health technologies to enhance patient engagement. Research into specific genetic, hormonal, and lifestyle factors that contribute to PMS could offer insights for more targeted interventions. The PMS treatment market is dynamic, with continuous demand for effective solutions that provide comprehensive symptom relief. Businesses have the potential to capitalize on unmet needs by focusing on patient-centric approaches, creating awareness campaigns to reduce stigma, and collaborating with healthcare professionals to optimize treatment protocols, thereby fostering market growth and improving patient outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 1.72 billion
Estimated Year [2024] USD 1.79 billion
Forecast Year [2030] USD 2.32 billion
CAGR (%) 4.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Premenstrual Syndrome Treatment Market

The Premenstrual Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing awareness of diagnosis regarding premenstrual syndrome
    • Easy availability of PMS treatment products through online channels
  • Market Restraints
    • Issues associated with product recalls for PMS drugs and devices
  • Market Opportunities
    • Advancements in therapy for PMS and the emergence of novel drugs
    • Adoption of wearable technology and the proliferation of digital health
  • Market Challenges
    • Societal barriers and stigmatization regarding PMS management

Porter's Five Forces: A Strategic Tool for Navigating the Premenstrual Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Premenstrual Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Premenstrual Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Premenstrual Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Premenstrual Syndrome Treatment Market

A detailed market share analysis in the Premenstrual Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Premenstrual Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Premenstrual Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Premenstrual Syndrome Treatment Market

A strategic analysis of the Premenstrual Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Premenstrual Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Alfa Pharma GmbH, Asarina Pharma AB., ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma, Bayer AG, Cadila Pharmaceuticals., Comforte Cream by PMS4PMS, LLC, Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Mylan N.V., Par Pharmaceutical, Inc, Pfizer Inc., Samphire Neuroscience, Shine Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Himalaya Drug Company, and Vitane Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Premenstrual Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Antidepressants, Diuretics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and Oral Contraceptives & Ovarian Suppression Agents.
  • Based on Type, market is studied across Over-the-Counter and Prescription.
  • Based on Distribution Channel, market is studied across E-commerce, Hospitals, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness of diagnosis regarding premenstrual syndrome
      • 5.1.1.2. Easy availability of PMS treatment products through online channels
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with product recalls for PMS drugs and devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapy for PMS and the emergence of novel drugs
      • 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
    • 5.1.4. Challenges
      • 5.1.4.1. Societal barriers and stigmatization regarding PMS management
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Emerging utilization of oral contraceptives for managing PMS symptoms due to their dual role in birth control and symptom management
    • 5.2.2. Distribution Channel: Emerging preference for e-Commerce distribution channels due to customer need for convenient shopping
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Premenstrual Syndrome Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antidepressants
  • 6.3. Diuretics
  • 6.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 6.5. Oral Contraceptives & Ovarian Suppression Agents

7. Premenstrual Syndrome Treatment Market, by Type

  • 7.1. Introduction
  • 7.2. Over-the-Counter
  • 7.3. Prescription

8. Premenstrual Syndrome Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. E-commerce
  • 8.3. Hospitals
  • 8.4. Retail Pharmacies

9. Americas Premenstrual Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Premenstrual Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Premenstrual Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
    • 12.3.2. Thirty Madison Delivers Continuity Of Care For Thousands Through Strategic Asset Purchase From The Pill Club, Strengthening Its Position In Women's Health
    • 12.3.3. London-Based Neurotech Start-Up Develops Medical Device For Menstrual Symptoms
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AA Pharma Inc.
  • 2. Alfa Pharma GmbH
  • 3. Asarina Pharma AB.
  • 4. ASKA Pharmaceutical Co., Ltd.
  • 5. Aurobindo Pharma
  • 6. Bayer AG
  • 7. Cadila Pharmaceuticals.
  • 8. Comforte Cream by PMS4PMS, LLC
  • 9. Dr. Reddy's Laboratories Inc.
  • 10. GlaxoSmithKline plc
  • 11. Intas Pharmaceuticals Ltd.
  • 12. Lupin Limited
  • 13. Mylan N.V.
  • 14. Par Pharmaceutical, Inc
  • 15. Pfizer Inc.
  • 16. Samphire Neuroscience
  • 17. Shine Pharmaceuticals Limited
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. The Himalaya Drug Company
  • 21. Vitane Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PREMENSTRUAL SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023